GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The pathobiology of Parkinson's disease (PD) is associated with the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) projecting to the striatum. Currently, there are no treatments that can halt or reverse the course of PD; only palliative therapies, such as replacement strategies for missing neurotransmitters, exist. Thus, the successful brain delivery of neurotrophic factors that promote neuronal survival and reverse the disease progression is crucial. We demonstrated earlier systemically administered autologous macrophages can deliver nanoformulated antioxidant, catalase, to the SNpc providing potent anti-inflammatory effects in PD mouse models. Here we evaluated genetically-modified macrophages for active targeted brain delivery of glial cell-line derived neurotropic factor (GDNF). To capitalize on the beneficial properties afforded by alternatively activated macrophages, transfected with GDNF-encoded pDNA cells were further differentiated toward regenerative M2 phenotype. A systemic administration of GDNF-expressing macrophages significantly ameliorated neurodegeneration and neuroinflammation in PD mice. Behavioral studies confirmed neuroprotective effects of the macrophage-based drug delivery system. One of the suggested mechanisms of therapeutic effects is the release of exosomes containing the expressed neurotropic factor followed by the efficient GDNF transfer to target neurons. Such formulations can serve as a new technology based on cell-mediated active delivery of therapeutic proteins that attenuate and reverse progression of PD, and ultimately provide hope for those patients who are already significantly disabled by the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079 · cited 1×
“A growing body of evidence indicates the usefulness and efficacy of neurotrophic factors for the treatment of PD [11–17].”
BackgroundFunctional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955 · cited 1×
“[15,17,23–25].”
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
Tieu, K., Perier, C., Caspersen, C., Teismann, P., Wu, D.-C., Yan, S.-D., Naini, A., Vila, M., Jackson-Lewis, V., Ramasamy, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318797 · Cited by 497
Bilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., & Horellou, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8818 · Cited by 297 · cited 1×
“A growing body of evidence indicates the usefulness and efficacy of neurotrophic factors for the treatment of PD [11–17].”
BackgroundGarcia, P., Youssef, I., Utvik, J. K., Florent-Béchard, S., Barthélémy, V., Malaplate-Armand, C., Kriem, B., Stenger, C., Koziel, V., Olivier, J.-L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4182-09.2010 · Cited by 139 · cited 1×
“Furthermore, transfected NSC were used for delivery of neurotrophic factors [39–43] in Alzheimer’s disease mouse model.”
Method
Cited by
Exosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Using exosomes, naturally-equipped nanocarriers, for drug delivery
Batrakova, E. V., & Kim, M. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.07.030 · Cited by 1,041
Self-citationJia, G., Han, Y., An, Y., Ding, Y., He, C., Wang, X., & Tang, Q. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.029 · Cited by 753
Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain
Yuan, D., Zhao, Y., Banks, W. A., Bullock, K. M., Haney, M., Batrakova, E., & Kabanov, A. V. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.07.011 · Cited by 607
“The Mφ exosomes can mediate the transfer of their cargo t o other brain resident cells [12, 14, 19, 20], or facilitate spreading of viruses and virus proteins from periphery to and within the brain [21, 22].”
InfluentialSelf-citationExosomes as therapeutics: The implications of molecular composition and exosomal heterogeneity
Ferguson, S. W., & Nguyen, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.037 · Cited by 416
Brief update on endocytosis of nanomedicines
Patel, S., Kim, J., Herrera, M., Mukherjee, A., Kabanov, A. V., & Sahay, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.004 · Cited by 400
Self-citationThe Exosome ‐ A Naturally Secreted Nanoparticle and its Application to Wound Healing
Rani, S., & Ritter, T. (2016) · Advanced Materials · doi:10.1002/adma.201504009 · Cited by 296
T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases
González, H., & Pacheco, R. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0201-8 · Cited by 266
Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers
Das, C. K., Jena, B. C., Banerjee, I., Das, S., Parekh, A., Bhutia, S. K., & Mandal, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00901 · Cited by 263
Xu, M., Feng, T., Liu, B., Qiu, F., Xu, Y., Zhao, Y., & Zheng, Y. (2021) · Theranostics · doi:10.7150/thno.62330 · Cited by 229
Self-citationOutside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
Troncoso-Escudero, P., Parra, A., Nassif, M., & Vidal, R. L. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00860 · Cited by 191
“In mice model of PD, intravenous-injected GDNF-transfected macrophages can cross the blood-brain barrier, reduce microglial activation and the loss of dopaminergic neurons in the SNpc, to improve the motor dysfunction observed in 6-OHDA-lesioned mice (111).”
BackgroundExtracellular Vesicles in Brain Tumors and Neurodegenerative Diseases
Ciregia, F., Urbani, A., & Palmisano, G. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00276 · Cited by 110
“By ELISA quantification of cargo proteins they examined the Ab42-generating system and found that γ-secretase, ADE levels of β-site amyloid precursor protein-cleaving enzyme 1, soluble amyloid precursor protein (sAPP)β, soluble Aβ42, sAPPα, glial-derived neurotrophic factor (GDNF), P-S396-tau, and P-T181-tau were sign…”
BackgroundInfluentialTentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109
Personalized nanomedicine for CNS diseases
Kaushik, A., Jayant, R. D., Bhardwaj, V., & Nair, M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.010 · Cited by 95
Treatment of Oxidative Stress with Exosomes in Myocardial Ischemia
Liu, Y., Wang, M., Liang, Y., Wang, C., Naruse, K., & Takahashi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041729 · Cited by 42
“In addition, catalase exosomes can be obtained by modifying parent cells (monocytes/macrophages) and then isolating from the conditioned medium [80].”
BackgroundThe Dichotomous Role of Extracellular Vesicles in the Central Nervous System
Graykowski, D. R., Wang, Y.-Z., Upadhyay, A., & Savas, J. N. (2020) · iScience · doi:10.1016/j.isci.2020.101456 · Cited by 39
Zhao, Y., Haney, M. J., Fallon, J. K., Rodriguez, M., Swain, C. J., Arzt, C. J., Smith, P. C., Loop, M. S., Harrison, E. B., El-Hage, N., et al. (2022) · Cells · doi:10.3390/cells11121933 · Cited by 39
“At each time point, the EVs were isolated from the conditioned media, and the GDNF levels in the cells and EVs media were assessed by ELISA, as described earlier [40].”
MethodResultInfluentialSelf-citationGlia-derived extracellular vesicles in parkinson’s disease.
Marchetti, B., Leggio, L., L’Episcopo, F., Vivarelli, S., Tirolo, C., Paternò, G., Giachino, C., Caniglia, S., Serapide, M. F., & Iraci, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061941 · Cited by 38
Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools
Palazzolo, S., Memeo, L., Hadla, M., Duzagac, F., Steffan, A., Perin, T., Canzonieri, V., Tuccinardi, T., Caligiuri, I., & Rizzolio, F. (2020) · Cancers · doi:10.3390/cancers12113165 · Cited by 34
Liu, X., Shen, L., Wan, M., Xie, H., & Wang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02428-1 · Cited by 33
Role of Glia-Derived Extracellular Vesicles in Neurodegenerative Diseases
Li, T., Tan, X., Li, S., Al-Nusaif, M., & Le, W. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.765395 · Cited by 33
Metadata
- Authors
- Zhao, Y., Haney, M. J., Gupta, R., Bohnsack, J. P., He, Z., Kabanov, A. V., & Batrakova, E. V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-09-17
- Volume
- 9
- Issue
- 9
- Pages
- e106867
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1976769213
- Cited by
- 145
- References
- 7
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.